초록 ▼

The present invention relates to PTP04 polypeptides, nucleic acids encoding such polypeptides, cells, tissues and animal containing such nucleic acids, antibodies to such polypeptides, assays utilizing such polypeptides, and methods relating to all of the foregoing. Methods for treatment, diagnosis,

The present invention relates to PTP04 polypeptides, nucleic acids encoding such polypeptides, cells, tissues and animal containing such nucleic acids, antibodies to such polypeptides, assays utilizing such polypeptides, and methods relating to all of the foregoing. Methods for treatment, diagnosis, and screening are provided for PTP04 related diseases or conditions characterized by an abnormal interaction between a PTP04 binding partner.

대표청구항 ▼

1. An isolated, enriched, or purified PTP04 polypeptide, wherein said polypeptide comprises:(a) an amino acid sequence comprising at least 90% identity to the full length amino acid sequence set forth in SEQ ID NO: 2; (b) an amino acid sequence comprising a sequence having at least 90% identity over

1. An isolated, enriched, or purified PTP04 polypeptide, wherein said polypeptide comprises:(a) an amino acid sequence comprising at least 90% identity to the full length amino acid sequence set forth in SEQ ID NO: 2; (b) an amino acid sequence comprising a sequence having at least 90% identity over the length of amino acid residues 49-294 of SEQ ID NO: 2, and lacking amino acid residues 1-48 of SEQ ID NO: 2; (c) an amino acid sequence comprising a sequence having at least 90% identity over the length of amino acid residues 49-294 of SEQ ID NO:2; or (d) an amino acid sequence comprising a sequence having at least 90% identity over the length of amino acid residues 49-294 of SEQ ID NO:2 and lacking amino acid residues 1-48 or amino acid residues 295-807, wherein said polypeptide possesses an enzymatic activity of a tyrosine phosophatase. 2. The polypeptide of claim 1, wherein said polypeptide comprises an amino acid sequence comprising at least 95% identity to the full length amino acid sequence set forth in SEQ ID NO: 2.3. The polypeptide of claim 1 wherein said polypeptide comprises the full length amino acid sequence set forth in SEQ ID NO: 2.4. The polypeptide of claim 1, wherein said polypeptide comprises a sequence having at least 95% identity over the length of amino acid residues 49-294 of SEQ ID NO: 2.5. The polypeptide of claim 1, wherein said polypeptide comprises the amino acid sequence set forth in amino acid residues 49-294 of SEQ ID NO: 2.6. The polypeptide of claim 1 wherein said polypeptide comprises a sequence having at least 95% identity over the length of amino acid residues 49-294 of SEQ ID NO:2 and lacking amino acid residues 1-48 or 295-807 of SEQ ID NO: 2.7. The polypeptide of claim 1 wherein said polypeptide comprises the full length amino acid sequence set forth in SEQ ID NO: 2 except it lacks amino acid residues 1-48 or 295-407 of SEQ ID NO:2.8. An isolated, enriched or purified polypeptide comprising the polypeptide of claim 1 fused to a second polypeptide.9. The isolated, enriched or purified polypeptide of claim 8, wherein said second polypeptide is hemagglutinin or GST.10. A composition comprising the polypeptide of claim 1 and a pharmaceutically acceptable carrier.